Delin, containing Dequalinium Chloride, is commonly applied across two distinct therapeutic domains where supportive relief for symptoms related to physical discomfort is needed.

---

Relief for Symptomatic Vaginal Infections

Delin is commonly used in gynaecological therapeutic domains to help with conditions presenting with systemic or localized discomfort, such as bacterial vaginosis (BV) and those of fungal origin, including vulvovaginal candidiasis (VVC), as well as trichomoniasis. It is applied in addressing symptom clusters that include malodorous discharge, vulvovaginal itching, and burning or irritation. This treatment is relevant in contexts involving inflammatory or irritative processes and is applied in scenarios where additional management of discomfort is required. The intended benefit is easing the overall symptom load, which helps with coping with symptom fluctuations. It may also be relevant in clinical contexts that involve temporary use as supportive relief before procedures, such as childbirth and gynaecological surgery.

---

Management of Oral and Throat Discomfort

The medication is relevant in clinical settings marked by acute discomfort and inflammation in the mouth and throat, commonly used to help with minor throat infections, pharyngitis, and stomatitis. It is applied in addressing symptoms related to inflammatory or irritative states, such as acute sore throat, throat pain, and discomfort associated with mouth ulcers or oral candidiasis. The use generally supports the patient during symptomatic episodes by easing distress and assists with maintaining general well-being during such phases.

---

Quick Facts: Used for managing symptoms related to Sore Throat and Vaginal Irritation in acute episodes.

Regulatory References

1. FDA Verification Portal

Who can and cannot use Delin?

The official regulatory documents define the eligibility for Delin (Dequalinium Chloride) based on specific constraints regarding age, local physical conditions, and physiological status. Eligibility is classified using the terms contraindicated, not recommended, and permitted (with conditions).

Absolute Contraindications The medicine is strictly contraindicated for patients with a documented hypersensitivity to the active substance or its excipients. It must not be used by pre-menarcheal girls who have not yet reached their first menstruation. Use is also prohibited in patients with ulceration of the vaginal epithelium and the cervix.

Age and Data Restrictions Standard use is established for adult women aged 18 to 55 years. Due to insufficient efficacy and safety data in other groups, the medicine is not recommended for women over 55 years or for children and adolescents under 18 years of age.

Conditional Use and Limitations Use is generally permitted during pregnancy if clearly necessary, and during breastfeeding. However, the medicine must not be used within 12 hours before expected childbirth (parturition). No specific limitations are documented for severe renal or hepatic impairment.

Interactions with other medicines and products — official regulatory information for Delin

Interaction Scope

The regulatory interaction profile for Dequalinium Chloride is determined by its local action and negligible systemic absorption, meaning no clinically significant systemic drug–drug interactions are known or established.

Medicinal product categories with documented interactions: Anionic substances, including soaps, detergents, surfactants, and spermicides.

Specific interacting medicines (if explicitly listed): Phenol and Chlorocresol.

Mechanistic basis of interactions (only if stated in label): The documented interactions are based on a chemical incompatibility where anionic substances reduce the treatment’s antimicrobial activity.

Timing-based interaction rules: The use of non-latex condoms and other intravaginal devices (e.g., diaphragms) is officially discouraged for a minimum of 12 hours following completion of the vaginal treatment course.

Interaction Classifications (High-Level)

Interaction severity classification: Clinically significant local incompatibility (resulting in reduced efficacy).

Interaction-context constraints: Restrictions apply exclusively to local chemical or physical agents at the site of administration.

Resulting Interaction Structure

Official interaction statements:

• The use of anionic substances and related products (soaps, vaginal washes, spermicides) is discouraged due to chemical incompatibility.
• Co-administration with phenol or chlorocresol is documented as incompatible.
• The functionality of latex condoms is officially stated as not impaired by the vaginal tablets.

The regulatory profile is defined entirely by constraints related to local activity, confirming that no systemic pharmacokinetic or pharmacodynamic drug–drug interactions are established in official prescribing information.

Direct Physical Destruction of the Microbial Cell Membrane

The primary mechanism involves the bis-quaternary ammonium compound physically engaging the pathogen's surface. The molecule’s positive charge binds instantaneously to the negatively charged phospholipid bilayer of bacteria and fungi. This binding destabilizes the membrane, leading to the formation of pores and results in rapid leakage of intracellular components (e.g., K^+ ions, nucleotides). This action contributes to a rapid, cidal-level physiological consequence by physically shattering the cell's integrity.

---

Internal Metabolic Shutdown and Genetic Interference

Following the membrane breach, the compound quickly enters the microbe to continue its multi-targeted attack inside the cell. Once internalized, it acts as an inhibitor of key respiratory enzymes (like F1-ATPase) and the entire glycolysis pathway, shutting down energy production (ATP). Concurrently, it interferes with the microbial DNA and RNA, blocking the synthesis of essential proteins and genetic replication. This dual internal action contributes to metabolic collapse and elimination of the pathogen, which contributes to the localized elimination of the microbial population.

---

Localized Action and Mechanism Limitations

The drug's mechanism is intrinsically linked to achieving a high local concentration to overwhelm and disrupt microbial targets. Local action is a key factor in the mechanism's function, but also its primary constraint: the mechanism may be less effective when the target microorganisms are protected within complex biofilm structures. Furthermore, high concentrations of biological substances like serum proteins or pus at the application site can partially bind the active compound, slightly reducing the available free fraction necessary for its rapid cidal effect.

How to Use Delin: Administration Guidelines

This section outlines the standard usage instructions for products marketed as Delin or Deline. All details pertain to the drug's administration and preparation, excluding therapeutic uses or safety information.

Administration Scope

Entity	Instruction
Route of Administration	Intravenous (IV) injection and Oral forms (Capsule/Tablet)
Dosing Schedule	Dosage is prescribed by a healthcare professional and is adjusted based on the patient's age, body weight, and underlying condition
Timing in Relation to Meals	Oral forms can be taken with or without food
Preparation Requirements	IV injection is administered slowly over 10 to 15 minutes by a trained medical professional to avoid adverse reactions

Procedural and Age-Group Rules

Age-Group Administration: Dosage calculation is performed with caution for children and elderly patients (over 55 years). The oral form is not recommended for children below 8 years of age except in life-threatening circumstances.

Special Procedural Conditions: When taking the oral form, the medicine is swallowed with a sufficient amount of water, and the patient remains upright for at least 30 minutes afterward to prevent esophageal irritation. Treatment is completed for the entire duration prescribed by the physician.

Missed Dose: If a dose is missed, it is taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose is skipped, and the regular schedule resumed. The dose is not doubled to compensate.

Research evidence / Overview of studies for Delin

This section outlines the types of clinical studies and research conducted for the medicine containing Dequalinium Chloride (Delin), detailing what outcomes were measured and where research data remain limited or uncertain. This is an overview of research patterns, not a guide to treatment or outcomes.

---

Evidence for Use in Bacterial Vaginosis (BV)

Research on the medicine containing Dequalinium Chloride explored its application in conditions characterized by fluctuating or episodic manifestations such as Bacterial Vaginosis (BV). Researchers primarily conducted large-scale randomized controlled trials (RCTs), which is a study type used to assess outcomes. These studies explored outcomes related to systemic or functional imbalance by measuring the rate of outcomes defined as cure criteria based on standard diagnostic criteria, as well as the microscopic changes in the bacterial balance.

Studies monitored participants over short-term periods (e.g., 7 to 11 days after starting treatment) and intermediate-term periods (up to 12 weeks). Research examined how patient-reported symptoms, such as discharge and odor, evolved in the observed populations. The research describes patterns observed in the study results, where the measured clinical and microbiological changes were evaluated for consistency with the changes observed using established treatments in those research settings.

Comparing Delin to Other Established Treatments for BV

Research explored the measurements of the treatment relative to other common first-line treatments for BV, such as certain oral and vaginal antibiotics. These specific non-inferiority trials were designed to see if the measured outcomes fell within an expected statistical range compared to the standard therapies. The evidence contributes to the broader evidence landscape by providing context on the measured response of Dequalinium Chloride relative to these other researched options.

---

Evidence for Use in Aerobic Vaginitis (AV)

The evidence base exploring the application of this medicine in Aerobic Vaginitis (AV) is generally characterized by smaller-scale clinical trials and placebo-controlled studies, meaning the evidence quality varies across studies. Research examined outcomes related to physical discomfort by tracking changes in a Total Symptom Score, which is applied in studies examining patient-reported experiences of discharge, itching, and burning. Studies also monitored the changes in microscopic flora grading.

Research describes the measurements of symptom scores relative to those who received an inactive control (placebo). However, sample sizes were modest, and the follow-up durations were limited, generally restricting the observations to short-term symptom changes occurring within approximately one week after the study period concluded.

Common questions about Delin (FAQ)

Q: How quickly can someone expect Delin to start working?

A: Official information indicates the active compound begins to act against microbes very quickly, within an hour of application. Official information indicates that symptom relief, such as changes in discharge and inflammation, has been observed within one to three days in studies.

Q: Are there any common over-the-counter medicines that interact with Delin?

A: Systemic interactions with other drugs are not expected because the medicine is designed for local action and has minimal absorption into the bloodstream. However, official regulatory information cautions against using certain anionic substances—such as some soaps, detergents, and spermicides—at the application site due to a chemical incompatibility that could reduce the medicine's activity.

Q: What types of food or drink should be avoided while using Delin?

A: According to official product information, there are no specific foods or drinks that need to be avoided while using this medicine. The oral forms of the medicine are generally described as being able to be taken with or without food.

Q: Is it safe to use Delin with vitamins or supplements?

A: The active ingredient acts primarily at the site of application, and minimal systemic absorption is expected. For this reason, official regulatory documents indicate that systemic drug-drug interactions with vitamins or supplements are unlikely.

Q: Are there any known interactions between Delin and herbal remedies?

A: The medicine acts locally and has negligible systemic absorption, meaning no clinically significant systemic interactions with herbal remedies are typically expected. Herbal remedies are not specifically listed as an interaction in official documents.

Q: What is Delin typically prescribed for?

A: The vaginal tablet formulation of Dequalinium Chloride (Delin) is officially prescribed for the treatment of bacterial vaginosis (BV) in adult women. This is the primary indication listed in regulatory documents for this dosage form.

Q: Is Delin used to treat conditions other than its main use?

A: Yes, the active ingredient in Delin, Dequalinium Chloride, is also used in other preparations. These include lozenges, which are approved for managing minor infections of the mouth and throat, such as tonsillitis or oral thrush.

Q: Does Delin affect the ability to drive or operate machinery?

A: Effects on the ability to drive or use heavy machinery are not anticipated. This is based on the official product information, which notes that the medicine has minimal systemic absorption and acts locally.

Q: What makes Delin different from other similar treatments?

A: The drug's mechanism is described as distinct because it works by physically disrupting the cell membrane of the microbe, causing it to break down. Clinical trials have explored its measured results relative to other established treatments, with evidence indicating non-inferiority based on measured clinical outcomes in those specific research settings.

Q: What happens if Delin is taken for a long period of time?

A: The standard treatment for the vaginal tablet formulation is intended for a short duration, generally six days. Regulatory documents state that exceeding the recommended duration of use for the vaginal tablet form may be associated with an increased risk of specific local adverse effects, including irritation or vaginal ulcerations.

Q: Can Delin affect sleep patterns?

A: Insomnia or sleep disturbance is not listed as a known or suspected adverse reaction in the official safety data available for the medicine.

Q: Has Delin been approved in countries outside the U.S.?

A: Yes, products containing the active ingredient Dequalinium Chloride have been approved and are available under various brand names across multiple countries, particularly in Europe and other international regions.

Q: What should be done if someone accidentally takes too much Delin?

A: In case of accidental ingestion, effects such as nausea, abdominal pain, and vomiting have been reported. Official information notes that a vaginal lavage (wash) procedure is documented for healthcare professionals to consider in cases of overdose with the vaginal tablet form.

Q: Is Delin available as a generic medicine?

A: The active substance, Dequalinium Chloride, is an established generic name recognized internationally. It is marketed globally under several different brand names.

Q: What is the typical timeframe for reviewing treatment with Delin?

A: The treatment course itself is typically six days. Regulatory research and clinical trials usually schedule patient follow-up visits to assess effectiveness shortly after the treatment ends, such as around seven days, and again approximately 25 days later.

Q: Can Delin cause dizziness or lightheadedness?

A: Dizziness or lightheadedness is not listed as a known or suspected adverse reaction in the official safety information for this medicine.

Q: Is Delin intended for long-term or short-term use?

A: According to official prescribing information, Delin is intended for short-term use. The standard course of treatment for the vaginal tablet formulation is typically set at six days.

Q: Does Delin require a special prescription or monitoring?

A: The vaginal tablet formulation is a prescription drug, meaning a healthcare professional must authorize its use. However, because it is minimally absorbed into the body, official information indicates that routine systemic monitoring, such as regular blood tests, is generally not required.

Q: Can Delin be crushed or split before use?

A: The vaginal tablet is designed for deep insertion as a whole. Official regulatory information mentions that if the vagina is very dry, moistening the tablet with a small amount of water prior to insertion may be done to aid dissolution.

Q: Do research papers indicate a clear benefit from Delin?

A: Clinical trials have explored the use of Delin for conditions like bacterial vaginosis. Evidence indicates that the treatment, when studied, measured outcomes that included clinical cure and microbiological changes. These changes were found to be consistent with those measured when using other established treatments in the research settings.

How to Store and Dispose of Delin (Dequalinium Chloride)

The official labeling provides strict storage requirements for Delin to maintain its stability and effectiveness, depending on the dosage form.

---

Storage Conditions

Dosage Form	Maximum Temperature	Protection Requirements
Vaginal Tablet	Below mathbf30 C	Protect from moisture and light
Lozenge	Below mathbf25 C	Protect from moisture and light

Storage must always be in the original container with the packaging tightly closed. The product must be stored in a dry place, and should not be frozen. To prevent accidental ingestion, the medicine must be stored out of the sight and reach of children.

---

Disposal Instructions

Expired or unused Delin must not be discarded into household trash or wastewater (drains). Disposal must strictly follow local regulations. Patients should consult their pharmacist or local waste management authority for instructions on how to properly discard the unused product.